CD274 and neoplasm: In addition, there were significant differences in 3-year survival rate between mesenchymal PD-L1-positive and PD-L1-negative patients when categorized by the following variables (Table 3): tumor stage (I-II; 0% vs. 100%, p = 0.034), heterologous subtype (0% vs. 75.0%, p = 0.048), small tumor volume (0% vs. 50.0%, p = 0.004).